Evidence map›Paper›PMID 38512619›Full record

ArticleLa Radiologia medica2024

The risk-based breast screening (RIBBS) study protocol: a personalized screening model for young women.

Gisella Gennaro, Lauro Bucchi, Alessandra Ravaioli, Manuel Zorzi, Fabio Falcini, Francesca Russo, Francesca Caumo

Registry-linked trialAbstract read
In one paragraph

Article in La Radiologia medica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05675085 (Risk-Based Breast Screening), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05675085 naunknown statusnot on this map

Risk-Based Breast Screening (RIBBS) in Young Women: Personalized Imaging Protocols

TypeinterventionalSponsorIstituto Oncologico Veneto IRCCSRan2020 to 2026Enrolled10,269ConditionsBreast NeoplasmsArmsPersonalized screening protocol
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Real-world data and evidence: pioneering frontiers in precision oncology.Journal of Zhejiang University. Science. B · 2025
    Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gisella GennaroVeneto Institute of Oncology (IOV) IRCCS, Padua, Italy.
Lauro BucchiEmilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy. lauro.bucchi@irst.emr.it.ORCID http://orcid.org/0000-0002-6771-8119
Alessandra RavaioliEmilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy.
Manuel ZorziSER - Servizio Epidemiologico Regionale e Registri, Azienda Zero, Padua, Italy.
Fabio FalciniEmilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy.
Francesca RussoDirezione Prevenzione, Sicurezza Alimentare, Veterinaria, Regione del Veneto, Venice, Italy.
Francesca CaumoVeneto Institute of Oncology (IOV) IRCCS, Padua, Italy.ORCID http://orcid.org/0000-0002-9457-5176

Funding

Regione del Veneto 2018Regione del Veneto 968/DGR of Jul 06
6 · The paper itself

Abstract

The optimal mammography screening strategy for women aged 45-49 years is a matter of debate. We present the RIBBS study protocol, a quasi-experimental, prospective, population-based study comparing a risk- and breast density-stratified screening model (interventional cohort) with annual digital mammography (DM) screening (observational control cohort) in a real-world setting. The interventional cohort consists of 10,269 women aged 45 years enrolled between 2020 and 2021 from two provinces of the Veneto Region (northen Italy). At baseline, participants underwent two-view digital breast tomosynthesis (DBT) and completed the Tyrer-Cuzick risk prediction model. Volumetric breast density (VBD) was calculated from DBT and the lifetime risk (LTR) was estimated by including VBD among the risk factors. Based on VBD and LTR, women were classified into five subgroups with specific screening protocols for subsequent screening rounds: (1) LTR ≤ 17% and nondense breast: biennial DBT; (2) LTR ≤ 17% and dense breast: biennial DBT and ultrasound; (3) LTR 17-30% or LTR > 30% without family history of BC, and nondense breast: annual DBT; (4) LTR 17-30% or > 30% without family history of BC, and dense breast: annual DBT and ultrasound; and (5) LTR > 30% and family history of BC: annual DBT and breast MRI. The interventional cohort is still ongoing. An observational, nonequivalent control cohort of 43,000 women aged 45 years participating in an annual DM screening programme was recruited in three provinces of the neighbouring Emilia-Romagna Region. Cumulative incidence rates of advanced BC at three, five, and ten years between the two cohorts will be compared, adjusting for the incidence difference at baseline.Trial registration This study is registered on Clinicaltrials.gov (NCT05675085).

Indexed as

Breast DensityBreast NeoplasmsEarly Detection of CancerMammographyFemaleHumansItalyMass ScreeningMiddle AgedProspective StudiesRisk AssessmentRisk FactorsBreast cancerBreast densityCancer screeningDigital Breast TomosynthesisRisk assessment

Identifiers

PMID38512619
PMCPMC11088554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.